United States - English - NLM (National Library of Medicine)

h.j. harkins company, inc. - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 500 mg -   - pharyngitis/tonsillitis caused by streptococcus pyogenes.   note: the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. cefuroxime axetil tablets are generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefuroxime in the subsequent prevention of rheumatic fever are not available. please also note that in all clinical trials, all isolates had to be sensitive to both penicillin and cefuroxime. there are no data from adequate and well-controlled trials to demonstrate the effectiveness of cefuroxime in the treatment of penicillin-resistant strains of streptococcus pyogenes.   - acute bacterial otitis media caused by streptococcus pneumoniae , haemophilus influenzae (including beta-lactamase–producing strains), moraxella catarrhalis (including beta-lactamase–producing strains), or streptococcu

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - cefuroxime axetil - oral tablet - 250mg

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients (13 years and older) with mild-to-moderate pharyngitis/tonsillitis caused by susceptible strains of streptococcus pyogenes. limitations of use - the efficacy of cefuroxime axetil in the prevention of rheumatic fever was not established in clinical trials. - the efficacy of cefuroxime axetil in the treatment of penicillin-resistant strains of streptococcus pyogenes has not been demonstrated in clinical trials. cefuroxime axetil tablets are indicated for the treatment of pediatric patients (who can swallow tablets whole) with acute bacterial otitis media caused by susceptible strains of streptococcus pneumoniae , haemophilus influenzae (including β-lactamase–producing strains), moraxella catarrhalis (including β-lactamase–producing strains), or streptococcus pyogenes . cefuroxime axetil tablets are indicated for the treatment of adult and pediatric patients (13 years and older) with mild-to-moderate acute bacte

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime axetil tablets, usp are indicated for the treatment of adult patients and pediatric patients (13 years and older) with mild-to-moderate pharyngitis/tonsillitis caused by susceptible strains of streptococcus pyogenes . limitations of use - the efficacy of cefuroxime axetil tablets, usp in the prevention of rheumatic fever was not established in clinical trials. - the efficacy of cefuroxime axetil tablets, usp in the treatment of penicillin-resistant strains of streptococcus pyogenes has not been demonstrated in clinical trials. cefuroxime axetil tablets, usp are indicated for the treatment of pediatric patients (who can swallow tablets whole) with acute bacterial otitis media caused by susceptible strains of streptococcus   pneumoniae , haemophilus influenzae (including β - lactamase-producing strains), moraxella catarrhalis (including β - lac

New Zealand - English - Medsafe (Medicines Safety Authority)

multichem nz limited - cefuroxime sodium 1.6 g equivalent to cefuroxime 1.5 g;   - powder for injection - 1.5 g - active: cefuroxime sodium 1.6 g equivalent to cefuroxime 1.5 g   - cefuroxime is a bactericidal cephalosporin antibiotic which is resistant to most ?-lactamases and is active against a wide range of gram-positive and gram-negative organisms. it is indicated for the treatment of infections before the infecting organism has been identified or when caused by sensitive bacteria. susceptibility to cefuroxime sodium will vary with geography and time and local susceptibility data should be consulted where available (see section 5.1). indications include - respiratory tract infections for example, acute and chronic bronchitis, infected bronchiectasis, bacterial pneumonia, lung abscess and post-operative chest infections. - ear, nose and throat infections for example, sinusitis, tonsillitis, pharyngitis and otitis media. - urinary tract infections for example, acute and chronic pyelonephritis, cystitis and asymptomatic bacteriuria. - soft-tissue infections for example, cellulitis, erysipelas and wound infections. - bone and joint infections for example, osteomyelitis and septi

Malta - English - Medicines Authority

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - cefuroxime - film-coated tablet - cefuroxime 250 mg - antibacterials for systemic use

Malta - English - Medicines Authority

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - cefuroxime - film-coated tablet - cefuroxime 500 mg - antibacterials for systemic use

Ireland - English - HPRA (Health Products Regulatory Authority)

milpharm limited - cefuroxime axetil (amorphous) - film coated tablet - 250 milligram - cephalosporins and related substances - antibacterials for systemic use, second-generation cephalosporins - cefuroxime milpharm is indicated for the treatment of the infections listed below in adults and children from the age of 3 months • acute streptococcal tonsillitis and pharyngitis. • acute bacterial sinusitis. • acute otitis media. • acute exacerbations of chronic bronchitis. • cystitis. • pyelonephritis. • uncomplicated skin and soft tissue infections. • treatment of early lyme disease.

United States - English - NLM (National Library of Medicine)

a-s medication solutions - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 250 mg - cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients (13 years and older) with mild-to-moderate pharyngitis/tonsillitis caused by susceptible strains of streptococcus pyogenes . limitations of use - the efficacy of cefuroxime axetil in the prevention of rheumatic fever was not established in clinical trials. -  the efficacy of cefuroxime axetil in the treatment of penicillin-resistant strains of streptococcus pyogenes has not been demonstrated in clinical trials. cefuroxime axetil tablets are indicated for the treatment of pediatric patients (who can swallow tablets whole) with acute bacterial otitis media caused by susceptible strains of streptococcus pneumoniae, haemophilus influenzae (including β-lactamase–producing strains), moraxella catarrhalis (including β-lactamase–producing strains), or streptococcus pyogenes . cefuroxime axetil tablets are indicated for the treatment of adult and pediatric patients (13 years and older) with mild-to-moderate acute ba

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cefuroxime axetil, quantity: 300.72 mg (equivalent: cefuroxime, qty 250 mg) - tablet, film coated - excipient ingredients: propylene glycol; microcrystalline cellulose; croscarmellose sodium; hydrogenated vegetable oil; hypromellose; methyl hydroxybenzoate; colloidal anhydrous silica; propyl hydroxybenzoate; sodium lauryl sulfate; titanium dioxide; purified water; sodium benzoate; industrial methylated spirit - cefuroxime is indicated for the treatment of the following mild to moderately severe infections in adults caused by sensitive bacteria. . acute upper respiratory infections: otitis media, sinusitis, tonsillitis and pharyngitis. . acute exacerbations of chronic bronchitis, or acute bronchitis. . skin and skin structure infections, for example, furunculosis, pyoderma and impetigo. . acute uncomplicated gonococcal urethritis, and cervicitis due to non-penicillinase producing gonococci.